<DOC>
	<DOC>NCT00864812</DOC>
	<brief_summary>Study title - A randomized, open label, multicenter, phase 4 study for the comparison of efficacy of tiotropium plus salmeterol/ fluticasone propionate compared with tiotropium alone in COPD patients Study objectives - To investigate clinical outcomes of combining tiotropium with fluticasone propionate/salmeterol (FSC) 250/50Î¼g bid compared with tiotropium alone in patients with moderate or severe COPD in Korea Study Design - Randomized, open-label, multicenter, parallel-group, two group study Study assessment - FEV1 - Inspiratory capacity (IC) - History of COPD exacerbation - History of hospitalization for COPD exacerbation and all causes - QoL (SGRQ-C)</brief_summary>
	<brief_title>Clinical Outcomes of Tiotropium Plus Fluticasone Propionate/Salmeterol Compared With Tiotropium for Chronic Obstructive Pulmonary Disease (COPD) in Korea</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Subjects Aged 40 to 80 years. Subjects diagnosed with COPD. Tobacco smoking 10 packyears or more. Subjects with postbronchodilator FEV1/FVC &lt; 0.7 and FEV1 &lt; 65% predicted. Subjects with a history of physiciandiagnosed asthma or a respiratory disorder other than COPD which is clinically significant such as diffuse bilateral bronchiectasis. Subjects suffering from serious diseases likely to interfere with the study such as chronic congestive heart failure. Subjects who used systemic corticosteroids within 4 weeks prior to study entry. Subjects with any malignant disease. Subjects with a history of severe glaucoma, urinary tract obstruction. Previous lung volume reduction surgery. Subjects who are pregnant or breastfeeding. Subjects with a known hypersensitivity or intolerance to tiotropium or fluticasonesalmeterol.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2010</verification_date>
</DOC>